Literature DB >> 10698594

Hormone resistance caused by mutations in G proteins and G protein-coupled receptors.

A M Spiegel1.   

Abstract

G proteins couple receptors for many hormones to effectors that regulate second messenger metabolism. Several endocrine disorders have been shown to be caused by either loss or gain of function mutations in G proteins or G protein-coupled receptors. Pseudohypoparathyroidism (PHP), the first described example of a hormone resistance disorder, is characterized by renal resistance to parathyroid hormone (PTH) proximal to generation of the second messenger, cAMP. In PHP Ia there is more generalized hormone resistance (PTH, TSH, gonadotropins) and associated abnormal physical features, Albright hereditary osteodystrophy (AHO). Subjects with PHP Ib are normal in appearance and resistant exclusively to PTH. Germline loss of function mutations have been identified in the Gs-alpha gene in PHP Ia, and recent evidence suggests that the Gs-alpha gene is paternally imprinted in a tissue-specific manner. In PHP Ib, several studies have excluded PTH receptor gene mutations, and the molecular basis has not yet been defined.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10698594

Source DB:  PubMed          Journal:  J Pediatr Endocrinol Metab        ISSN: 0334-018X            Impact factor:   1.634


  4 in total

1.  Validation of fumonisin biomarkers in F344 rats.

Authors:  Qingsong Cai; Lili Tang; Jia-Sheng Wang
Journal:  Toxicol Appl Pharmacol       Date:  2007-08-16       Impact factor: 4.219

2.  Cutaneous nodules and a novel GNAS mutation in a Chinese boy with pseudohypoparathyroidism type Ia: A case report and review of literature.

Authors:  Yun-Ling Li; Ting Han; Fang Hong
Journal:  World J Clin Cases       Date:  2020-02-06       Impact factor: 1.337

3.  Pseudohypoparathyroidism type Ib associated with novel duplications in the GNAS locus.

Authors:  Gustavo Perez-Nanclares; Teresa Velayos; Amaya Vela; Manuel Muñoz-Torres; Luis Castaño
Journal:  PLoS One       Date:  2015-02-24       Impact factor: 3.240

Review 4.  Targeting Lysophosphatidic Acid in Cancer: The Issues in Moving from Bench to Bedside.

Authors:  Yan Xu
Journal:  Cancers (Basel)       Date:  2019-10-10       Impact factor: 6.639

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.